Proceedings of International Conference on Applied Innovation in IT  ·  2026/03/31  ·  Vol. 14  ·  Issue 1  ·  pp. 877–884
Correlation Analysis of Cardiac and Biochemical Markers in Cardiovascular Disease
Nabaa H Al-Obiady, Noor Kadhim Ahmed, Saja Khalil Mohuee, Salima K. Ahmed and Salma Hamid Issa
📄 Download PDF DOI: 10.25673/123649
Abstract
Higher body mass index (BMI) can be a risk for cardiovascular disease: however, the original causal links are still not clear. Objective: The study aims at determining relationship between BMI and cardio vascular disease. Patients and methods: Sixty situation, Thirty of them were male and thirty were female throughout of the study from January to February 2020 in AL-ZAHRAA Hospital. We recorded the medical history, body weight, height and BMI. The age ranged from (17 to74) years. In this study both were measured Aspartate aminotransferase (AST), Cholesterol, Triglyceride, Low Density Lipoprotein (LDL-Cho), High Density Lipoprotein (HDL-Cho), High Sensitive Troponin I (TNHS) and Atergenic Index Very Low Density Lipoprotein (VLDL-Cho), Lactate Dehydrogenase(LDH), Creatine Kinase (CK), that measured the three types (Under Weight, Normal Weight and Over Weight). Results and Discussion: The mean anthropometric are indices in sera of the experimental groups. The results of the study showed the male situation (50%) was equal than female situation percentage (50%) with none significant differences (p>0.05) between these groups. Also, the mean value of Cholesterol is higher in over weight than normal and underweight with high significant differences(p<0.001) that mean ± SD for over, normal and underweight were (205.70±62.67), (146.60±49.59) and (137.40±33.71) mg/dl respectively. Triglyceride, (LDL-Cho) and Very (LDL-Cho) also high on overweight, but HDL-Cho is high on the underweight compared with other groups.
Keywords
Cardiovascular Body Mass Index Lipid Profile and Troponin.
References
  1. P. D. Loprinzi, C. J. Crespo, R. E. Andersen, and E. Smit, “Association of Body Mass Index with Cardiovascular Disease Biomarkers,” American Journal of Preventive Medicine, vol. 48, no. 3, pp. 338-344, Mar. 2015, [Online]. Available: https://doi.org/10.1016/j.amepre.2014.08.019.
  2. A. B. Gregory, K. K. Lester, D. M. Gregory, L. K. Twells, W. K. Midodzi, and N. J. Pearce, “The Relationship between Body Mass Index and the Severity of Coronary Artery Disease in Patients Referred for Coronary Angiography,” Cardiology Research and Practice, vol. 2017, pp. 1-10, 2017, [Online]. Available: https://doi.org/10.1155/2017/5481671.
  3. K. R. Fontaine, D. T. Redden, C. Wang, A. O. Westfall, and D. B. Allison, “Years of life lost due to obesity,” JAMA, vol. 289, no. 2, pp. 187-93, Jan. 2003, [Online]. Available: https://doi.org/10.1001/jama.289.2.187.
  4. K. M. Flegal, B. K. Kit, H. Orpana, and B. I. Graubard, “Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories,” JAMA, vol. 309, no. 1, p. 71, Jan. 2013, [Online]. Available: https://doi.org/10.1001/jama.2012.113905.
  5. M. Volpe and G. Gallo, “Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC),” Frontiers in Cardiovascular Medicine, vol. 10, Mar. 2023, [Online]. Available: https://doi.org/10.3389/fcvm.2023.1136340.
  6. A. Ceriello et al., “Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register,” Cardiovascular Diabetology, vol. 20, no. 1, Aug. 2021, [Online]. Available: https://doi.org/10.1186/s12933-021-01360-0.
  7. A. Tarek Abd Elaziz, M. A. Eldeeb, M. A. Mannaa, and A. S. El-Damanhory, “Relation between Central Obesity and Severity of Coronary Artery Disease in Patients Undergoing Coronary Angiography,” Zagazig University Medical Journal, vol. 0, no. 0, Dec. 2024, [Online]. Available: https://doi.org/10.21608/zumj.2024.339844.3707.
  8. S. Simati, A. Kokkinos, M. Dalamaga, and G. Argyrakopoulou, “Obesity Paradox: Fact or Fiction?,” Current Obesity Reports, Feb. 2023, [Online]. Available: https://doi.org/10.1007/s13679-023-00497-1.
  9. S. C. Larsson, M. Bäck, J. M. B. Rees, A. M. Mason, and S. Burgess, “Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study,” European Heart Journal, vol. 41, no. 2, pp. 221-226, Jun. 2019, [Online]. Available: https://doi.org/10.1093/eurheartj/ehz388.
  10. T. Zhang et al., “Diversified Shifts in the Cross Talk between Members of the Gut Microbiota and Development of Coronary Artery Diseases,” Microbiology Spectrum, vol. 10, no. 6, p. e0280422, Spring 2022, [Online]. Available: https://doi.org/10.1128/spectrum.02804-22.
  11. S. D. Phillips and W. C. Roberts, “Comparison of body mass index among patients with versus without angiographic coronary artery disease,” The American Journal of Cardiology, vol. 100, no. 1, pp. 18-22, Jan. 2007, [Online]. Available: https://doi.org/10.1016/j.amjcard.2007.02.048.
  12. B. Richter, B. Hemmingsen, M.-I. Metzendorf, and Y. Takwoingi, “Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia,” Cochrane Database of Systematic Reviews, Oct. 2018, [Online]. Available: https://doi.org/10.1002/14651858.cd012661.pub2.
  13. M. N. Shalaby and Marwa Ahmed Fadl, “Relative Indicators and Predicative Ability of Some Biological Variables on Cardiac Neural Activity for Volleyball Players,” Systematic Reviews in Pharmacy, vol. 11, no. 9, pp. 834-840, 2020, [Online]. Available: https://doi.org/10.31838/srp.2020.9.119.
  14. S. K. Ahmed, Salwa H. N. Al-Rubae’i, H. H. Murbat, and M. R. Mohammed, “Inactivation of HCV using non-thermal plasma technology and study liver enzyme and biochemical parameters,” AIP Conference Proceedings, vol. 3229, pp. 020003-020003, Jan. 2024, [Online]. Available: https://doi.org/10.1063/5.0237044.
  15. W. A. Davis, V. Hellbusch, M. L. Hunter, D. G. Bruce, and Timothy, “Contemporary Cardiovascular Risk Assessment for Type 2 Diabetes Including Heart Failure as an Outcome: The Fremantle Diabetes Study Phase II,” Journal of Clinical Medicine, vol. 9, no. 5, pp. 1428-1428, May 2020, [Online]. Available: https://doi.org/10.3390/jcm9051428.
  16. A. P. Kengne et al., “Contemporary model for cardiovascular risk prediction in people with type 2 diabetes,” European Journal of Cardiovascular Prevention & Rehabilitation, vol. 18, no. 3, pp. 393-398, Feb. 2011, [Online]. Available: https://doi.org/10.1177/1741826710394270.
  17. C. R. Elley, E. Robinson, T. Kenealy, D. Bramley, and P. L. Drury, “Derivation and Validation of a New Cardiovascular Risk Score for People With Type 2 Diabetes: The New Zealand Diabetes Cohort Study,” Diabetes Care, vol. 33, no. 6, pp. 1347-1352, Mar. 2010, [Online]. Available: https://doi.org/10.2337/dc09-1444.
  18. X. Yang et al., “Development and Validation of a Total Coronary Heart Disease Risk Score in Type 2 Diabetes Mellitus,” The American Journal of Cardiology, vol. 101, no. 5, pp. 596-601, Dec. 2007, [Online]. Available: https://doi.org/10.1016/j.amjcard.2007.10.019.
  19. C. S. Smith, P. A. Bottomley, S. P. Schulman, G. Gerstenblith, and R. G. Weiss, “Altered Creatine Kinase Adenosine Triphosphate Kinetics in Failing Hypertrophied Human Myocardium,” Circulation, vol. 114, no. 11, pp. 1151-1158, Sep. 2006, [Online]. Available: https://doi.org/10.1161/circulationaha.106.613646.
  20. I. A. Amin, “The Effect of Atenolol on CK-MB Levels in Hypertensive Patients,” Iraqi Journal of Pharmaceutical Sciences, vol. 18, no. 1, pp. 61-64, Mar. 2017, [Online]. Available: https://doi.org/10.31351/vol18iss1pp61-64.
  21. K. Thygesen, J. S. Alpert, H. D. White, and Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, “Universal definition of myocardial infarction,” European Heart Journal, vol. 28, no. 20, pp. 2525-38, 2007, [Online]. Available: https://doi.org/10.1093/eurheartj/ehm355.
  22. E. Kopel, S. Kivity, N. Morag-Koren, S. Segev, and Y. Sidi, “Relation of Serum Lactate Dehydrogenase to Coronary Artery Disease,” The American Journal of Cardiology, vol. 110, no. 12, pp. 1717-1722, Dec. 2012, [Online]. Available: https://doi.org/10.1016/j.amjcard.2012.08.005.
  23. P. K. Nigam, “Biochemical markers of myocardial injury,” Indian Journal of Clinical Biochemistry, vol. 22, no. 1, pp. 10-17, Mar. 2007, [Online]. Available: https://doi.org/10.1007/bf02912874.
  24. J. E. Adams and V. A. Miracle, “Cardiac biomarkers: past, present, and future,” American Journal of Critical Care, vol. 7, no. 6, pp. 418-23, Nov. 1998, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/9805114/.
  25. M. Y. Hsu, M. M. Kohler, L. Barolia, and R. J. Bondar, “Separation of five isoenzymes of serum lactate dehydrogenase by discontinuous gradient elution from a miniature ion-exchange column,” Clinical Chemistry, vol. 25, no. 8, pp. 1453-8, Aug. 1979, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/455684/.
  26. R. McPherson, “Henry’s Clinical Diagnosis and Management by Laboratory Methods,” Advances in Anatomic Pathology, 2007.
  27. A. R. Shipman, S. Bahrani, and K. E. Shipman, “Investigative algorithms for disorders affecting plasma lactate dehydrogenase: a narrative review,” Journal of Laboratory and Precision Medicine, vol. 9, no. 0, Apr. 2024, [Online]. Available: https://doi.org/10.21037/jlpm-23-65.
  28. J. Christenson, “Acute coronary syndromes,” Canadian Medical Association Journal, vol. 171, no. 11, pp. 1322-1323, Nov. 2004, [Online]. Available: https://doi.org/10.1503/cmaj.1041331.
  29. D. C. Gaze and P. O. Collinson, “Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance,” Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, vol. 45, no. 4, pp. 349-355, Jul. 2008, [Online]. Available: https://doi.org/10.1258/acb.2007.007229.
  30. A. Jeremias and C. M. Gibson, “Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded,” Annals of Internal Medicine, vol. 142, no. 9, p. 786, May 2005, [Online]. Available: https://doi.org/10.7326/0003-4819-142-9-200505030-00015.
  31. J. Bleier et al., “Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage,” Clinical Chemistry, vol. 44, no. 9, pp. 1912-1918, Sep. 1998, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/9732976/.
  32. H. Hussain, “Evaluating of some heart and liver enzymes in patients with myocardial infarction in Wasit,” Wasit Journal of Pure Sciences, vol. 2, no. 4, pp. 166-176, Dec. 2023, [Online]. Available: https://doi.org/10.31185/wjps.253.
  33. M. Yokoyama et al., “Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up,” Disease Markers, vol. 2016, pp. 1-9, 2016, [Online]. Available: https://doi.org/10.1155/2016/4857917.
  34. W. L. Miller and B. P. Mullan, “Peripheral Venous Hemoglobin and Red Blood Cell Mass Mismatch in Volume Overload Systolic Heart Failure: Implications for Patient Management,” Journal of Cardiovascular Translational Research, vol. 8, no. 7, pp. 404-410, Sep. 2015, [Online]. Available: https://doi.org/10.1007/s12265-015-9650-4.
  35. S. Fishbane and A. Besarab, “Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 6, pp. 1274-1282, Oct. 2007, [Online]. Available: https://doi.org/10.2215/cjn.02380607.
  36. I. Arocha, Trina Navas Blanco, P. Amair, and Rusvel Gómez Berroterán, “Clinical implications of iron deficiency/anemia in heart failure and approach to the treatment,” Revista Colombiana de Nefrología, vol. 3, no. 1, pp. 26-40, Jan. 2016, [Online]. Available: https://doi.org/10.22265/acnef.3.1.238.
  37. G. F. Strippoli, G. Tognoni, S. D. Navaneethan, A. Nicolucci, and J. C. Craig, “Haemoglobin targets: we were wrong, time to move on,” The Lancet, vol. 369, no. 9559, pp. 346-350, Feb. 2007, [Online]. Available: https://doi.org/10.1016/s0140-6736(07)60165-2.
  38. I. Pusceddu, B. Dieplinger, and T. Mueller, “ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans,” Clinica Chimica Acta, vol. 495, pp. 493-500, Aug. 2019, [Online]. Available: https://doi.org/10.1016/j.cca.2019.05.023.
  39. S. Savarimuthu, P. Goel, and A. Harky, “Soluble ST2: a valuable prognostic marker in heart failure,” Heart Failure Reviews, vol. 27, no. 6, pp. 2155-2164, Nov. 2022, [Online]. Available: https://doi.org/10.1007/s10741-022-10258-2.
  40. E. O’Meara et al., “Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial,” Circulation: Heart Failure, vol. 11, no. 5, May 2018, [Online]. Available: https://doi.org/10.1161/circheartfailure.117.004446.
  41. J. Sharim and L. B. Daniels, “Soluble ST2 and Soluble Markers of Fibrosis: Emerging Roles for Prognosis and Guiding Therapy,” Current Cardiology Reports, vol. 22, no. 6, p. 41, 2020, [Online]. Available: https://doi.org/10.1007/s11886-020-01288-z.
  42. J. L. Januzzi et al., “Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea,” Journal of the American College of Cardiology, vol. 50, no. 7, pp. 607-613, Aug. 2007, [Online]. Available: https://doi.org/10.1016/j.jacc.2007.05.014.

Proceedings of the International Conference on Applied Innovations in IT by Anhalt University of Applied Sciences is licensed under CC BY-SA 4.0  ·  This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License

ICAIIT 2026
International Conference on Applied Innovation in IT
Navigation
Publisher
ISSN2199-8876
Publisher Edition Hochschule Anhalt
Location Anhalt University of Applied Sciences
Email leiterin.hsb@hs-anhalt.de
Phone +49 (0) 3496 67 5611
Address Building 01, Room 425
Bernburger Str. 55
D-06366 Köthen, Germany
Open Access License
CC BY-SA 4.0

All works are licensed under the Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), unless otherwise noted.

Published by ICAIIT in cooperation with Anhalt University of Applied Sciences.

© 2026 ICAIIT — International Conference on Applied Innovations in IT. Anhalt University of Applied Sciences, Köthen, Germany.
Visitors: site traffic counter